- Home
- MDWD vs STXS Comparison
MDWD vs STXS Comparison
Compare MDWD & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- STXS
- Stock Information
- Founded
- MDWD 2000
- STXS 1990
- Country
- MDWD Israel
- STXS United States
- Employees
- MDWD N/A
- STXS N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MDWD Health Care
- STXS Health Care
- Exchange
- MDWD Nasdaq
- STXS Nasdaq
- Market Cap
- MDWD 184.8M
- STXS N/A
- IPO Year
- MDWD 2014
- STXS 2004
- Fundamental
- Price
- MDWD $20.50
- STXS $2.53
- Analyst Decision
- MDWD Strong Buy
- STXS Strong Buy
- Analyst Count
- MDWD 1
- STXS 2
- Target Price
- MDWD $25.00
- STXS $4.50
- AVG Volume (30 Days)
- MDWD 78.0K
- STXS 412.8K
- Earning Date
- MDWD 03-20-2025
- STXS 03-03-2025
- Dividend Yield
- MDWD N/A
- STXS N/A
- EPS Growth
- MDWD N/A
- STXS N/A
- EPS
- MDWD N/A
- STXS N/A
- Revenue
- MDWD $19,720,000.00
- STXS $25,143,000.00
- Revenue This Year
- MDWD $10.15
- STXS $3.73
- Revenue Next Year
- MDWD $25.62
- STXS $54.27
- P/E Ratio
- MDWD N/A
- STXS N/A
- Revenue Growth
- MDWD N/A
- STXS N/A
- 52 Week Low
- MDWD $11.04
- STXS $1.66
- 52 Week High
- MDWD $24.00
- STXS $3.29
- Technical
- Relative Strength Index (RSI)
- MDWD 57.75
- STXS 61.33
- Support Level
- MDWD $18.73
- STXS $2.26
- Resistance Level
- MDWD $19.73
- STXS $2.52
- Average True Range (ATR)
- MDWD 0.78
- STXS 0.13
- MACD
- MDWD 0.02
- STXS 0.03
- Stochastic Oscillator
- MDWD 66.35
- STXS 88.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.